RNAZ TransCode Therapeutics, Inc.
Listings ·
Nasdaq told TransCode on May 19, 2026 that its stockholders' equity of $1,251,427 is below the $2,500,000 minimum. The company has until July 3, 2026 to submit a plan to regain compliance, and its equity had been $10,335,466 at December 31, 2025.
TransCode blames the complexity of accounting for its October 2025 deal with DEFJ, LLC, including a roughly $25 million Series B preferred placement. It expects to file within the extension period.
After the deal, CK Life Sciences would hold about 91% of TransCode on a fully diluted basis, and existing holders about 9%. Converting the preferred stock needs stockholder approval where Nasdaq rules apply, and up to $95 million in milestones may go to CK Life Sciences.
TransCode received a Nasdaq notice on May 6, 2025 that its stock would be delisted from the Nasdaq Capital Market unless it appeals. Earlier reverse splits left it with no compliance period, so it must request a hearing by May 13, 2025.
TransCode said it needs time to account for a registered direct offering that closed on March 25, 2025. It expects to file within the Rule 12b-25 extension period.
TransCode is selling 10,250,000 shares and warrants at $0.98 per share and warrant, through ThinkEquity LLC as exclusive placement agent, for a total offering price of $10,045,000 before fees. The prospectus shows an immediate dilution of $0.72 per share to new investors, and the auditor's report carries a going concern paragraph.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $13.4 million | $9.7 million |
| Net income (loss) | -$34.7 million | -$16.8 million |
| Cash from operations | -$19.5 million | -$13.3 million |
| Cash and equivalents | $17.8 million | $5.8 million |
Our latest story on this, dated May 7, 2025: "TransCode Therapeutics faces Nasdaq delisting with no grace period, plans hearing". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 7, 2025: "TransCode Therapeutics faces Nasdaq delisting with no grace period, plans hearing". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 25, 2025: "TransCode Therapeutics agrees to sell 10,250,000 shares and warrants at $0.98". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 31, 2025: "TransCode Therapeutics delays 2024 annual report to account for direct offering". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 22, 2026: "TransCode Therapeutics gets Nasdaq stockholders' equity deficiency notice". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 8, 2025: "TransCode agrees to buy Polynoma and sell CK Life Sciences $25 million of preferred stock". The story links the filing or release it is based on. Read the story.
TransCode Therapeutics, Inc. trades under the ticker RNAZ on NASDAQ.
TransCode Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for TransCode Therapeutics, Inc. is 1829635. Its filings are on SEC EDGAR.
16,930,739 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-14.
Our directory records TransCode Therapeutics, Inc. under United States.
Our directory classifies TransCode Therapeutics, Inc. as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline.
The ISIN recorded for TransCode Therapeutics, Inc. is US89357L5012.
aibio.space lists TransCode Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Reported that a debt obligation was accelerated. SEC Form 8-K (Items 1.01,2.04). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,7.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,3.03,5.03,7.01,8.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.01,3.02,3.03,5.02,5.03,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.07,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.07,8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio